Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796448 | 0.87 | KDM4E (0.70) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL5485622 | 0.86 | HTR1A (0.73) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL1375643 | 0.86 | ALDH1A1 (0.69) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL4171468 | 0.86 | ALDH1A1 (0.65) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL3188003 | 0.85 | ALDH1A1 (0.71) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL11047857 | 0.85 | HTR1A (0.71) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL5796341 | 0.85 | MAPT (0.65) | KDM4EALDH1A1TDP1DRD2MEN1 | |
| Hydrochloric Acid SCHEMBL3196115 | 0.84 | HTR1A (0.71) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL6956822 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1TDP1DRD2HTR1A | |
| SCHEMBL7775626 | 0.83 | HTR1A (0.77) | KDM4EALDH1A1TDP1DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
| EP-0213326-B1 | 2,5-DIMETHYL PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4966901-A | FOR TREATMENT OF ALZHEIMER*S DISEASE, LEARNING OR MEMORY PROBLEMS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-10-30 | — | — | US | disclosed |
| EP-0346683-A1 | Pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1989-12-20 | — | — | EP | disclosed |
| US-4837225-A | ENCEPHALOTROPIC AND PSYCHOTROPIC EFFECTS | CASSELL AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0287988-A2 | Pyrrole aldehydes, their preparation and use | CASSELLA Aktiengesellschaft (DE) | 1988-10-26 | — | — | EP | disclosed |
| EP-0213326-A1 | 2,5-Dimethyl pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1987-03-11 | — | — | EP | disclosed |
| WO-1984004302-A1 | SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | KDM4E 1872/4885ALDH1A1 357/4885TDP1 3476/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | KDM4E 4278/4885ALDH1A1 706/4885TDP1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.